UMIN-CTR Clinical Trial

Public title

Preoperative chemotherapy followed by hepatic resection for resectable UICC7 StageIIIA, IIIB hepatocellular carcinoma, A phase II clinical trial

Acronym

Preoperative chemotherapy for resectable UICC7 StageIII HCC

Scientific Title

Preoperative chemotherapy followed by hepatic resection for resectable UICC7 StageIIIA, IIIB hepatocellular carcinoma, A phase II clinical trial

Scientific Title:Acronym

Preoperative chemotherapy for resectable UICC7 StageIII HCC

Region

Japan

Condition

hepatocellular carcinoma

Classification by specialty

Hepato-biliary-pancreatic medicine

Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO

Narrative objectives1

To analyze survival benefit of preoperative chemotherapy for in patients with resectable UICC StageIIIA, IIIB advanced hepatocellular carcinoma.

Basic objectives2

Efficacy

Basic objectives -Others

Trial characteristics_1

Trial characteristics_2

Developmental phase

Phase II

Primary outcomes

The 3 years disease free survival rate after liver surgery

Key secondary outcomes

Overall survival, disease free survival, response to the preoperative chemotherapy, incidence and degree of side effects of preoperative chemotherapy

Study type

Interventional

Basic design

Single arm

Randomization

Non-randomized

Randomization unit

Blinding

Open -no one is blinded

Control

Historical

Stratification

Dynamic allocation

Institution consideration

Blocking

Concealment

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

As a preoperative chemotherapy, hepatic arterial infusion chemotherapy (HAIC) is performed, regimen of HAIC is New FP therapy. Angiography is performed on Day 1 as induction New FP and bolus injection is performed by suspending Lipiodol at a maximum of 10 ml and CDDP at a maximum of 50 mg according to the tumor diameter. Lastly, infuser pump containing 1250 mg of 5-FU is connected and administered continuously from Day 1 to Day 5, this is taken as one course. After the introduction therapy by completing the second course from Day 8 and the third course from Day 15 (for the case where tumor vascular embolism is insufficient at the end of 3 courses, the 4th course from day 22 is conducted and the introduction chemotherapy is terminated ).
New FP maintenance chemotherapy suspends CDDP up to 35 mg for Lipiodol maximum of 5 ml on Day 1 and terminates bolus injection at the time when whole tumor is filled with Lipiodol under angiography or when Lipiodol stagnates in tumor blood vessel . Continuous administration of infuser pump containing 1000 mg of 5-FU, continuous administration from Day 1 to Day 3, this is taken as one course. Maintain total of 3-4 courses with biweekly chemotherapy and complete preoperative chemotherapy. If there was a feeding artery other than the hepatic artery existed, TACE is added.

Interventions/Control_2

Interventions/Control_3

Interventions/Control_4

Interventions/Control_5

Interventions/Control_6

Interventions/Control_7

Interventions/Control_8

Interventions/Control_9

Interventions/Control_10

Age-lower limit

20

years-old

<=

Age-upper limit

Not applicable

Gender

Male and Female

Key inclusion criteria

1) A case of aged> or =20 years old.
2) Cases of UICC7 StageIIIA, IIIB diagnosed as hepatocellular carcinoma histologically or clinically (imaging diagnosis, tumor marker).
3) Cases of UICC7 StageIIIA, IIIB which can initially perform R0 resection at diagnosis.
4) Cases in which patient consent was obtained in the document after adequate explanation by the attending physician.
5) Patients who can expect survival for more than 3 months.
6) ECOG performance status 0 or 1.
7) Patients who had been preserved adequate major organ functions within 2 weeks before registration (bone marrow, heart, liver, kidney, etc.).
Neutrophils> or =1000/mm3
Hb> or =8.5 g/dl
Platelet> or =75,000/mm3
AST and ALT< or =200 IU/L
Child-Pugh score 7 points or less
Total bilirubin 3 mg/dl or less (Excluded after reduction of jaundice cases due to bile duct tumor obstructions)
No refractory ascites or hepatic encephalopathy
Other major organ functions are well preserved

Key exclusion criteria

1) Patients with history of advanced cancer in other organs within 5 years.
2) A patient who has history of chemotherapy of a regimen including CDDP or 5-FU.
2) Active infectious diseases (except for viral hepatitis)
3) Patients who have a history of allergy to iodine contrast agent, platinum-containing drug, or gelatin-containing drug / food.
4) Pregnant women, breast-feeding women and patients who may be pregnant.
Patients who are determined by the attending physician to be inappropriate for this examination for other reasons (in cases where the patient does not obey the instructions or has problems with family cooperation etc.).

Target sample size

25

Name of lead principal investigator

1st name
Middle name
Last name	Koji Okuda

Organization

Kurume University

Division name

Department of Surgery, Division of Hepatobilliary and Pancreatic Surgery

Zip code

Address

67 Asahi-machi, Kurume-shi, Fukuoka, Japan

TEL

0942-31-7567

Email

kook@med.kurume-u.ac.jp

Name of contact person

1st name
Middle name
Last name	Yuichi Goto

Organization

Kurume University

Division name

Department of Surgery, Division of Hepatobilliary and Pancreatic Surgery

Zip code

Address

67 Asahi-machi, Kurume-shi, Fukuoka, Japan

TEL

0942-31-7567

Homepage URL

Email

gotou_yuuichi@med.kurume-u.ac.jp

Institute

Kurume University, Department of Surgery, Division of Hepatobilliary and Pancreatic Surgery

Institute

Department

Personal name

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Co-sponsor

Name of secondary funder(s)

Organization

Address

Tel

Email

Secondary IDs

NO

Study ID_1

Org. issuing International ID_1

Study ID_2

Org. issuing International ID_2

IND to MHLW

Institutions

Date of disclosure of the study information

2018

Year

01

Month

09

Day

URL releasing protocol

Publication of results

Unpublished

URL related to results and publications

Number of participants that the trial has enrolled

Results

Results date posted

Results Delayed

Results Delay Reason

Date of the first journal publication of results

Baseline Characteristics

Participant flow

Adverse events

Outcome measures

Plan to share IPD

IPD sharing Plan description

Recruitment status

Open public recruiting

Date of protocol fixation

2016

Year

10

Month

12

Day

Date of IRB

Anticipated trial start date

2016

Year

11

Month

01

Day

Last follow-up date

Date of closure to data entry

Date trial data considered complete

Date analysis concluded

Other related information

Registered date

2018

Year

01

Month

09

Day

Last modified on

2018

Year

01

Month

09

Day

Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035104